Edition:
India

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

173.39USD
19 Jul 2018
Change (% chg)

$-2.47 (-1.40%)
Prev Close
$175.86
Open
$174.95
Day's High
$174.95
Day's Low
$171.00
Volume
419,962
Avg. Vol
620,040
52-wk High
$256.78
52-wk Low
$142.83

Select another date:

Thu, Jul 19 2018

Photo

Allergan, Molecular Partners eye drug meets main goal in two studies

Allergan Plc and Molecular Partners AG said on Thursday their treatment for neovascular age-related macular degeneration, a leading cause of vision loss among people over 65, met the main goal in two late-stage studies.

UPDATE 1-Allergan, Molecular Partners eye drug meets main goal in two studies

July 19 Allergan Plc and Molecular Partners AG said on Thursday their treatment for neovascular age-related macular degeneration, a leading cause of vision loss among people over 65, met the main goal in two late-stage studies.

Allergan, Molecular Partners eye drug meets main goal in two studies

July 19 Allergan Plc and Molecular Partners AG said on Thursday their treatment for age-related macular degeneration met the main goal in two late-stage studies.

Allergan appoints former Abbott executive to its board

June 14 Allergan Plc said on Thursday former Abbott Laboratories executive Thomas Freyman will join its board, a week after two of its shareholders criticized the drugmaker's acquisition strategy and board composition.

Allergan oral migraine drug succeeds in study

June 11 Allergan Plc said on Monday its oral migraine drug met the main goal across all doses in a study, with a statistically significant reduction in monthly headache days in patients with episodic migraine.

Icahn buys small stake in drugmaker Allergan: sources

Billionaire investor Carl Icahn has acquired a small stake in Allergan Plc at a time when the drugmaker is under pressure from other activist shareholders, people familiar with the matter said on Wednesday.

Icahn buys small stake in drugmaker Allergan -sources

June 6 Billionaire investor Carl Icahn has acquired a small stake in Allergan Plc at a time when the drugmaker is under pressure from other activist shareholders, people familiar with the matter said on Wednesday.

UPDATE 2-Two Allergan shareholders call for split of chairman-CEO role

June 5 Two of Allergan Plc's shareholders, hedge funds Appaloosa Management and Senator Investment Group, asked the drugmaker's board to split the role of chief executive officer and chairman as well as reconsider its acquisition strategy.

Hedge fund Appaloosa asks Allergan to split chairman-CEO position

June 5 Billionaire investor David Tepper's hedge fund Appaloosa Management and Senator Investment Group on Tuesday asked Allergan Plc's board to split the office of the chief executive officer and chairman.

Allergan to sell women's health, infectious disease units

NEW YORK Drugmaker Allergan Plc said on Wednesday it plans to sell two of its smaller businesses, the women's health and infectious disease units, as Chief Executive Brent Saunders works to end a steep slide in its share price over the last year.

Select another date: